ProfileGDS5678 / 1428408_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 78% 81% 84% 80% 77% 77% 81% 80% 82% 78% 80% 80% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7072481
GSM967853U87-EV human glioblastoma xenograft - Control 25.4100678
GSM967854U87-EV human glioblastoma xenograft - Control 35.8475581
GSM967855U87-EV human glioblastoma xenograft - Control 46.3324284
GSM967856U87-EV human glioblastoma xenograft - Control 55.7118880
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0496177
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1312477
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8154881
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6136480
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9281282
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3901478
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6543280
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6671780
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6628980